Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Directorate Change

17 Oct 2017 07:00

RNS Number : 7490T
Premier Veterinary Group PLC
17 October 2017
 

PREMIER VETERINARY GROUP PLC

 

("PVG PLC", the "Company" or the "Group")

 

Directorate Change

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014.

 

London, UK, 17 October 2017 - Premier Veterinary Group plc (LSE: PVG) wishes to advise that Mr Iain Ross has resigned from his position as a Non-Executive Director of the Company, with effect from 16 October 2017, due to additional board responsibilities that he has elsewhere. The Board of Directors would like to thank Mr Ross for his service to the Company, and wish him all the best for his future endeavours.

 

 

-Ends-

 

For further information, please contact:

 

Premier Veterinary Group plc 

Tel: +44 (0)117 970 4130

Dominic Tonner, Chief Executive Officer 

 

Will Evans, Chief Financial Officer 

 

 

 

Note to Editors:

PVG's services to third party veterinary practices, through its wholly owned subsidiary, Premier Vet Alliance Limited ("PVA"), include the administration and support of a preventative healthcare programme for pets branded "Premier Pet Care Plan" ("PPCP"). In the US, where veterinary practices are known as veterinary hospitals, PPCP is marketed through the Company's wholly owned subsidiary, Premier Vet Alliance (US) Limited.

 

PPCP is a structured, preventative healthcare programme for cats, dogs and rabbits and is available only through veterinary practices/hospitals. The programme is seen as a way of providing gold standard care for pets at an affordable price for the client, by way of fixed monthly payments.

 

PPCP uses a clinical approach to prevention, as this is the most effective method of ensuring illnesses are diagnosed more quickly and not given a chance to advance. What truly sets PPCP apart is its unique approach of offering an end-to-end solution and support to the practice/hospital, which has been proven to work extremely well. PVA works alongside practices/hospitals to create a tailor-made, cost-effective service for clients, one that delivers excellent care to their patients and significantly improves practice/hospital performance.

For further details:

 

www.premiervetgroup.co.uk

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOABIBDGXBBBGRL
Date   Source Headline
14th Apr 20102:09 pmRNSRule 8.3- Ark Therapeutics Group PLC
14th Apr 201011:41 amRNSEPT Disclosure-Amendment
13th Apr 201012:08 pmBUSRule 8.3 - Ark Therapeutics Group plc
13th Apr 201011:34 amRNSEPT Disclosure
13th Apr 201011:31 amRNSRule 8.3- ARK THERAPEUTICS
13th Apr 201011:29 amRNSEPT Disclosure
12th Apr 201011:22 amRNSEPT Disclosure
12th Apr 201010:19 amRNSEPT Disclosure
12th Apr 20107:00 amRNSResearch Update
9th Apr 201011:35 amRNSEPT Disclosure
9th Apr 201011:33 amRNSEPT Disclosure- Amendment
9th Apr 20109:28 amRNSEPT Disclosure
8th Apr 20102:43 pmRNSEPT Disclosure-Amendment
8th Apr 201012:27 pmRNSEPT Disclosure
8th Apr 201010:43 amRNSRule 8.3- ARK THERAPEUTICS
8th Apr 20108:33 amRNSEPT Disclosure
7th Apr 20104:08 pmRNSAnnual Information Update
7th Apr 201010:59 amRNSRule 8.3- ARK THERAPEUTICS
1st Apr 201011:03 amRNSArk Therapeutics Group plc
1st Apr 201011:00 amRNSEPT Disclosure
1st Apr 201010:37 amRNSEPT Disclosure
31st Mar 20103:42 pmRNSTotal Voting Rights
31st Mar 20102:00 pmBUSRule 8.3 - ARK THERAPEUTICS GROUP PLC
31st Mar 201010:37 amRNSEPT Disclosure
30th Mar 201012:48 pmRNSEPT Disclosure
30th Mar 201012:42 pmBUSRule 8.3 - Ark Therapeutics Group plc
25th Mar 201012:08 pmBUSRule 8.3 - Ark Therapeutics Group plc
25th Mar 201010:53 amRNSEPT Disclosure
24th Mar 201011:52 amRNSEPT Disclosure
24th Mar 201011:15 amRNSEPT Disclosure
24th Mar 201010:25 amBUSRule 8.3 - Ark Therapeutics Group plc
22nd Mar 20101:48 pmRNSRule 8.3- ARK THERAPEUTICS GROUP PLC
22nd Mar 20101:42 pmRNSRule 8.3- ARK THERAPEUTICS GROUP PLC
22nd Mar 20101:24 pmBUSRule 8.3 - ARK THERAPEUTICS GROUP PLC
22nd Mar 201011:45 amRNSEPT Disclosure
22nd Mar 201010:18 amRNSEPT Disclosure
19th Mar 20104:58 pmRNSRule 8.3- (Ark Therapeutics Group Plc)
19th Mar 20102:56 pmRNSRule 8.3- Ark Therapeutics Group plc
19th Mar 20101:30 pmBUSRule 8.3 - Ark Therapeutics Group plc
19th Mar 201011:45 amRNSEPT Disclosure
19th Mar 201010:30 amRNSEPT Disclosure
18th Mar 201012:14 pmRNSEPT Disclosure
17th Mar 201010:38 amRNSEPT Disclosure
16th Mar 20103:55 pmRNSHolding(s) in Company
16th Mar 201011:12 amRNSEPT Disclosure
15th Mar 201011:30 amRNSEPT Disclosure
15th Mar 201010:34 amRNSEPT Disclosure
11th Mar 201011:49 amRNSEPT Disclosure
10th Mar 20104:40 pmRNSSecond Price Monitoring Extn
10th Mar 20104:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.